



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Equivalent of Form PTO/SB/08a (01-08)

Approved for use through 03/31/2008

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

**FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1 of 2

<i>Complete if Known</i>	
Application Number	10/684,268
Filing Date	October 10, 2003
First Named Inventor	MONTERO-JULIAN, Felix A.
Art Unit	1641
Examiner Name	FOSTER, Christine E.
Attorney Docket Number	2512.0230001/KWM/C-K

Digitized by srujanika@gmail.com

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If Known)			
	US1	4,048,298	09/13/1977	Niswender	
	US2	4,120,945	10/17/1978	Gutcho <i>et al.</i>	
	US3	4,228,237	10/14/1980	Hevey <i>et al.</i>	
	US4	4,478,946	10/23/1984	Van der Merwe <i>et al.</i>	
	US5	5,534,416	07/09/1996	Millard <i>et al.</i>	
	US6	5,583,031	12/10/1996	Stern	
	US7	5,734,023	03/31/1998	Nag <i>et al.</i>	
	US8	5,965,532	10/12/1999	Bachovchin	
	US9	6,037,135	03/14/2000	Kubo <i>et al.</i>	
	US10	6,355,479	03/12/2002	Webb <i>et al.</i>	
	US11	6,419,931	07/16/2002	Vitiello <i>et al.</i>	
	US12	2002/0006903 A1	01/17/2002	Schneck <i>et al.</i>	
	US13	2003/0044415 A1	03/06/2003	Savage	
	US14	2003/0191286 A1	10/09/2003	Hildebrand <i>et al.</i>	
	US15	2003/0044389 A1	03/06/2003	Brown <i>et al.</i>	
	US16	2004/0072262 A1	04/15/2004	Montero-Julian <i>et al.</i>	
	US17	2004/0253632 A1	12/16/2004	Rhode <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	FP1	WO 92/07952 A1	05/14/1992	Immulogic Pharma Corp. <i>et al.</i>		
	FP2	WO 95/04817 A1	02/16/1995	Cytel Corp.		
	FP3	WO 97/00067 A1	01/03/1997	University of Victoria		
	FP4	WO 97/004085 A1	02/06/1997	Boehringer Mannheim GmbH		
	FP5	WO 97/09429 A2	03/13/1997	Corixa Corp.		
	FP6	WO 98/23690 A1	06/04/1998	Eastman Chemical Co.		
	FP7	WO 01/90747 A2	11/29/2001	Sunol Molecular Corp.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/684,268
				Filing Date	October 10, 2003
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1641
				Examiner Name	FOSTER, Christine E.
Sheet	2	of	2	Attorney Docket Number	2512.0230001/KWM/C-K

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

826856v1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/684,268
Sheet	1	of	7	Filing Date	October 10, 2003
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1641
				Examiner Name	FOSTER, Christine E.
				Attorney Docket Number	2512.0230001/KWM/C-K

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	BODINIER, M., <i>et al.</i> , "Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding," <i>Nat. Med.</i> 6:707-710, Nature Publishing Company (2000)	
	NPL2	BUUS, S., <i>et al.</i> , "The Relation Between Major Histocompatibility Complex (MHC) Restriction and the Capacity of Ia to Bind Immunogenic Peptides," <i>Science</i> 235:1353-1358, American Association for the Advancement of Science (1987)	
	NPL3	CARBONE, F.R., and BEVAN, M.J., "Chapter 18: Major Histocompatibility Complex Control of T Cell Recognition," in <i>Fundamental Immunology 2nd Ed.</i> , Paul, W.E., ed., Raven Press Ltd., New York, NY, pp 541-567 (1989)	
	NPL4	CASON, J., <i>et al.</i> , "Analysis of human lymphocyte transformation responses to graded doses of T cell mitogens by curve fitting," <i>J. Immunol. Methods</i> 102:109-117, North-Holland Publishing Co. (1987)	
	NPL5	CELIS, E., <i>et al.</i> , "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 91:2105-2109, National Academy of Sciences (1994)	
	NPL6	CONSTANTIN, C.M., <i>et al.</i> , "Major Histocompatibility Complex (MHC) Tetramer Technology: An Evaluation," <i>Biol. Res. Nurs.</i> 4:115-127, Sage Publications, Inc. (October 2002)	
	NPL7	DORNMAIR, K., <i>et al.</i> , "Structural Intermediates in the Reactions of Antigenic Peptides with MHC Molecules," <i>Cold Spring Harb. Symp. Quant. Biol.</i> 54:409-416, Cold Spring Harbor Laboratory Press (1989)	
	NPL8	GELUK, A., <i>et al.</i> , "Identification of Major Epitopes of <i>Mycobacterium tuberculosis</i> AG85B That Are Recognized by HLA-A*0201-Restricted CD8 ⁺ T Cells in HLA-Transgenic Mice and Humans," <i>J. Immunol.</i> 165:6463-6471, The American Association of Immunologists (2000)	
	NPL9	GERRITSMA, J.S.J., <i>et al.</i> , "The Constant Domain of IgG Is a Possible Target Antigen for Immunotherapy of B Cell Malignancies in HLA-A1 Mismatched Transplantation," <i>Blood</i> 98:404a-405a, The American Society of Hematology (December 2001)	
	NPL10	GORGA, J.C., <i>et al.</i> , "Purification and Characterization of Class II Histocompatibility Antigens from a Homozygous Human B Cell Line," <i>J. Biol. Chem.</i> 262:16087-16094, The American Society for Biochemistry and Molecular Biology (1987)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/684,268
Sheet	2	of	7	Filing Date	October 10, 2003
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1641
				Examiner Name	FOSTER, Christine E.
				Attorney Docket Number	2512.0230001/KWM/C-K

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T ²
	NPL11	HANSEN, T.H., and SACHS, D.H., "Chapter 16: The Major Histocompatibility Complex," in <i>Fundamental Immunology 2nd Ed.</i> , Paul, W.E., ed., Raven Press Publishing, New York, NY, pp 445-487 (1989)			
	NPL12	HENDERSON, R.A., <i>et al.</i> , "Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:10275-10279, National Academy of Sciences (1993)			
	NPL13	HENGEL, H., <i>et al.</i> , "Frequency of Herpes Simplex Virus-Specific Murine Cytotoxic T Lymphocyte Precursors in Mitogen- and Antigen-Driven Primary <i>in vitro</i> T Cell Responses," <i>J. Immunol.</i> 139:4196-4202, The American Association of Immunologists (1987)			
	NPL14	HERR, W., <i>et al.</i> , "Detection and quantification of blood-derived CD8 ⁺ T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens," <i>J. Immunol. Methods</i> 191:131-142, North-Holland Publishing Co. (1996)			
	NPL15	HERR, W., <i>et al.</i> , "The use of computer-assisted video image analysis for the quantification of CD8 ⁺ T lymphocytes producing tumor necrosis factor α spots in response to peptide antigens," <i>J. Immunol. Methods</i> 203:141-152 North-Holland Publishing Co. (1997)			
	NPL16	HICKLING, J.K., <i>et al.</i> , "Varicella-Zoster Virus-Specific Cytotoxic T Lymphocytes (Tc): Detection and Frequency Analysis of HLA Class I-Restricted Tc in Human Peripheral Blood," <i>J. Virol.</i> 61:3463-3469, American Society For Microbiology (1987)			
	NPL17	HÖRIG, H., <i>et al.</i> , "An <i>in vitro</i> study of the dynamic features of the major histocompatibility complex class I complex relevant to its role as a versatile peptide-receptive molecule," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94:13826-13831, National Academy of Sciences (1997)			
	NPL18	HUGUES, S., <i>et al.</i> , "Generation and use of alternative multimers of peptide/MHC complexes," <i>J. Immunol. Methods</i> 268:83-92, North-Holland Publishing Co. (October 2002)			
	NPL19	HUNKAPILLER, M.W., <i>et al.</i> , "Isolation of Microgram Quantities of Proteins from Polyacrylamide Gels for Amino Acid Sequence Analysis," <i>Methods Enzymol.</i> 91:227-236, Academic Press (1983)			
	NPL20	KADIVAL, G.V., <i>et al.</i> , "Characterization of Serologic and Cell-Mediated Reactivity of a 38-kDa Antigen Isolated from <i>Mycobacterium tuberculosis</i> ," <i>J. Immunol.</i> 139:2447-2451, The American Association of Immunologists (1987)			
Examiner Signature			Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/684,268
				Filing Date	October 10, 2003
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1641
				Examiner Name	FOSTER, Christine E.
Sheet	3	of	7	Attorney Docket Number	2512.0230001/KWM/C-K

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL21	KAWAKAMI, Y., <i>et al.</i> , "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 91:3515-3519, National Academy of Sciences (1994)	
	NPL22	KAWAKAMI, Y., <i>et al.</i> , "Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes," <i>J. Exp. Med.</i> 180:347-352, Rockefeller University Press (1994)	
	NPL23	KUHNS, J.J., <i>et al.</i> , "Poor Binding of a HER-2/neu Epitope (GP2) to HLA-A2.1 Is Due to a Lack of Interactions with the Center of the Peptide," <i>J. Biol. Chem.</i> 274:36422-36427, The American Society for Biochemistry and Molecular Biology (1999)	
	NPL24	MAEURER, M.J., <i>et al.</i> , "Improved Detection of Melanoma Antigen-Specific T Cells Expressing Low or High Levels of CD8 by HLA-A2 Tetramers Presenting a Melan-A/Mart-1 Peptide Analogue," <i>Int. J. Cancer</i> 97:64-71, Wiley-Liss, Inc. (January 2002)	
	NPL25	MALE, D., "Chapter 2: Antibodies and Antigens," in <i>Immunology: An Illustrated Outline</i> , Bennet, D., ed., Gower Medical Publishing, London, England, p.19-34 (1986)	
	NPL26	MARX, J.L., "Histocompatibility Restriction Explained," <i>Science</i> 235:843-844, American Association for the Advancement of Science (1987)	
	NPL27	MEN, Y., <i>et al.</i> , "Assessment of Immunogenicity of Human Melan-A Peptide Analogues in HLA-A*0201/K ^b Transgenic Mice," <i>J. Immunol.</i> 162:3566-3573, The American Association of Immunologists (1999)	
	NPL28	ROBINSON, M.A., and KINDT, T.J., "Chapter 17: Major Histocompatibility Complex Antigens and Genes," in <i>Fundamental Immunology 2nd Ed.</i> , Paul, W.E., ed., Raven Press Ltd., New York, NY, pp 489-539 (1989)	
	NPL29	ROITT, I.M., <i>et al.</i> , eds., "Chapter 5: Antibody Structure and Function," in <i>Immunology</i> , Gower Medical Publishing, London, England, p.5.7, (1986)	
	NPL30	RUPPERT, J., <i>et al.</i> , "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," <i>Cell</i> 74:929-937, Cell Press (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/684,268
Sheet	4	of	7	Filing Date	October 10, 2003
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1641
				Examiner Name	FOSTER, Christine E.
				Attorney Docket Number	2512.0230001/KWM/C-K

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL31	SAMELSON, L.E., <i>et al.</i> , "T Cell Antigen Receptor Phosphorylation Induced by an Anti-Receptor Antibody," <i>J. Immunol.</i> 139:2708-2714, The American Association of Immunologists (1987)	
	NPL32	SETTE, A., <i>et al.</i> , "Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells," <i>Nature</i> 328:395-399, Nature Publishing Group (1987)	
	NPL33	SMITH, J.D., <i>et al.</i> , "Extensive peptide ligand exchange by surface class I major histocompatibility complex molecules independent of exogenous β_2 -microglobulin," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89:7767-7771, National Academy of Sciences (1992)	
	NPL34	SØRENSEN, A.L., <i>et al.</i> , "Purification and Characterization of a Low-Molecular-Mass T-Cell Antigen Secreted by <i>Mycobacterium tuberculosis</i> ," <i>Infect. Immun.</i> 63:1710-1717, American Society For Microbiology (1995)	
	NPL35	Springfrog, "Temperature Converter," accessed online at http://springfrog.com/converter/temperature.htm , 2 pages (accessed 2008)	
	NPL36	THORLEY-LAWSON, D.A., and ISRAELSOHN, E.S., "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 84:5384-5388, National Academy of Sciences (1987)	
	NPL37	TSIEN, R.Y., <i>et al.</i> , "T-cell mitogens cause early changes in cytoplasmic free Ca^{2+} and membrane potential in lymphocytes," <i>Nature</i> 295:68-71, Nature Publishing Group (1982)	
	NPL38	TSOMIDES, T.J., <i>et al.</i> , "An optimal viral peptide recognized by CD8 ⁺ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 88:11276-11280, National Academy of Sciences (1991)	
	NPL39	TURNER, M.J., <i>et al.</i> , "Purification of Papain-solubilized Histocompatibility Antigens from a Cultured Human Lymphoblastoid Line, RPMI 4265," <i>J. Biol. Chem.</i> 250:4512-4519, American Society for Biochemistry and Molecular Biology (1975)	
	NPL40	VALMORI, D., <i>et al.</i> , "Diversity of the Fine Specificity Displayed by HLA-A*0201-Restricted CTL Specific for the Immunodominant Melan-A/MART-1 Antigenic Peptide," <i>J. Immunol.</i> 161:6956-6962, The American Association of Immunologists (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/684,268
Sheet	5	of	7	Filing Date	October 10, 2003
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1641
				Examiner Name	FOSTER, Christine E.
				Attorney Docket Number	2512.0230001/KWM/C-K

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL41	VAN DER BURG, S.H., <i>et al.</i> , "An HLA Class I Peptide-Binding Assay Based on Competition for Binding to Class I Molecules on Intact Human B Cells. Identification of Conserved HIV-1 Polymerase Peptides Binding to HLA-A*0301," <i>Hum. Immunol.</i> 44:189-198, Elsevier/North-Holland (1995)	
	NPL42	VAN DER BURG, S.H., <i>et al.</i> , "Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability," <i>J. Immunol.</i> 156:3308-3314, The American Association of Immunologists (1996)	
	NPL43	"2006 Annual Immune Epitope Database and Discovery Workshop Meeting Report Executive Summary," at <i>The Third Annual Immune Epitope Database and Discovery Workshop</i> held on November 7 and 8, 2006 in North Bethesda, Maryland, 3 pages (January 2007)	
	NPL44	ARNOLD, P.Y., <i>et al.</i> , "The Majority of Immunogenic Epitopes Generate CD4 ⁺ T Cells That Are Dependent on MHC Class II-Bound Peptide-Flanking Residues," <i>J. Immunol.</i> 169:739-749, The American Association of Immunologists (July 2002)	
	NPL45	BELMARES, M.P., <i>et al.</i> , "Structural Factors Contributing to DM Susceptibility of MHC Class II/Peptide Complexes," <i>J. Immunol.</i> 169:5109-5117, The American Association of Immunologists (November 2002)	
	NPL46	BERCOVICI, N., <i>et al.</i> , "New Methods for Assessing T-Cell Responses," <i>Clin. Diagn. Lab. Immunol.</i> 7:859-864, American Society for Microbiology (2000)	
	NPL47	BODER, E.T., <i>et al.</i> , "Yeast Surface Display of a Noncovalent MHC Class II Heterodimer Complexed with Antigenic Peptide," <i>Biotechnol. Bioeng.</i> 92:485-491, Wiley (November 2005)	
	NPL48	CALL, M.E., <i>et al.</i> , "Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum," <i>EMBO J.</i> 23:2348-2357, Oxford University Press (June 2004)	
	NPL49	CALL, M.E., and Wucherpfennig, K.W., "The T Cell Receptor: Critical Role of the Membrane Environment in Receptor Assembly and Function," <i>Annu. Rev. Immunol.</i> 23:101-125, Annual Reviews (April 2005)	
	NPL50	DUTOIT, V., <i>et al.</i> , "Functional Avidity of Tumor Antigen-Specific CTL Recognition Directly Correlates with the Stability of MHC/Peptide Multimer Binding to TCR," <i>J. Immunol.</i> 168:1167-1171, American Association of Immunologists (February 2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/684,268
				Filing Date	October 10, 2003
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1641
				Examiner Name	FOSTER, Christine E.
Sheet	6	of	7	Attorney Docket Number	2512.0230001/KWM/C-K

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T ²
	NPL51	GRETEN, T.F., and SCHNECK, J.P., "Development and Use of Multimeric Major Histocompatibility Complex Molecules," <i>Clin. Diagn. Lab. Immunol.</i> 9:216-220, American Society for Microbiology (March 2002)		
	NPL52	KLEIN, J., and SATO, A., "The HLA System - Second of Two Parts," <i>N. Engl. J. Med.</i> 343:782-786, Massachusetts Medical Society (September 2000)		
	NPL53	MCMICHAEL, A.J., and KELLEHER, A., "The arrival of HLA class II tetramers," <i>J. Clin. Invest.</i> 104:1669-1670, American Society for Clinical Investigation (1999)		
	NPL54	NEPOM, G.T., <i>et al.</i> , "HLA Class II Tetramers - Tools for Direct Analysis of Antigen-Specific CD4+ T Cells," <i>Arthritis Rheum.</i> 46:5-12, Wiley-Liss, Inc. (January 2002)		
	NPL55	OGG, G.S., and MCMICHAEL, A.J., "HLA-peptide tetrameric complexes," <i>Curr. Opin. Immunol.</i> 10:393-396, Current Biology (1998)		
	NPL56	REICHSTETTER, S., <i>et al.</i> , "Distinct T Cell Interactions with HLA Class II Tetramers Characterize a Spectrum of TCR Affinities in the Human Antigen-Specific T Cell Response," <i>J. Immunol.</i> 165:6994-6998, The American Association of Immunologists (December 2000)		
	NPL57	RÖTZSCHKE, O., <i>et al.</i> , "Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes," <i>Proc. Natl. Acad. Sci. USA</i> 96:7445-7450, National Academy of Sciences (1999)		
	NPL58	SLIZ, P., <i>et al.</i> , "Crystal Structures of Two Closely Related but Antigenically Distinct HLA-A2/Melanocyte-Melanoma Tumor-Antigen Peptide Complexes," <i>J. Immunol.</i> 167:3276-3284, The American Association of Immunologists (September 2001)		
	NPL59	STONE, J.D., <i>et al.</i> , "T-Cell Activation by Soluble MHC Oligomers Can Be Described by a Two-Parameter Binding Model," <i>Biophys. J.</i> 81:2547-2557, Biophysical Society (November 2001)		
	NPL60	WELSH, R.M., "Assessing CD8 T Cell Number and Dysfunction in the Presence of Antigen," <i>J. Exp. Med.</i> 193:F19-F22, The Rockefeller University Press (March 2001)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				<p><i>Complete if Known</i></p>	
Sheet	7	of	7	Application Number	10/684,268
				Filing Date	October 10, 2003
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1641
				Examiner Name	FOSTER, Christine E.
				Attorney Docket Number	2512.0230001/KWM/C-K

NON-PATENT LITERATURE DOCUMENTS

826907v1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**